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1. Introduction 
Synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome is a rare disorder 
characterized by osteoarticular and dermatological manifestations. The denotation was first 
proposed by Chamot et al. in 1987 after investigation of 85 cases (Chamot et al., 1987). The 
most common site of SAPHO syndrome is the upper anterior chest wall, characterized by 
predominantly osteosclerotic lesions and hyperostosis. The axial skeleton and peripheral 
bones can be involved. Peripheral synovitis is also common. Skin manifestations include 
palmoplantar pustulosis (PPP), severe acne and various patterns of psoriasis. 
The pathogenesis of SAPHO syndrome has not been determined. Most of the reported series 
to date are anecdotal, small or uncontrolled, thus a variety of therapeutic approaches exist. 
Treatment remains empirical with several drugs including non-steroidal anti-inflammatory 
drugs (NSAIDs), corticosteroids, antibiotics, disease modifying anti-rheumatic drugs 
(DMARDs) and/or bisphosphonates (BPs), but results are inconsistent and usually variable. 
Recently, some successful experiences with anti-tumor necrosis factor-alpha (TNF-α) agents 
for refractory cases have been reported (Asmussen, 2003; Ben Abdelghani et al., 2010; 
Castellvi et al., 2010; Deutschmann et al., 2005; Iqbal & Kolodney, 2005; Kyriazis et al., 2004; 
Massara et al., 2006; Moll et al., 2008; Olivieri et al., 2002; Sabugo et al., 2008; Wagner et al., 
2002; Widmer et al., 2003). The therapeutic strategy was largely originated from that for 
spondyloarthropathies, because accumulated arguments indicate that SAPHO syndrome 
can be classified with the inflammatory spondyloarthropathies (Takigawa et al., 2008) and 
treatment with anti-TNF-α agents is now well established in spondyloarthropathies or 
rheumatoid arthritis (RA). Chronic proliferative synovitis is one of the most important 
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pathological features in RA, and proliferated synovium is a major source of 
proinflammatory cytokines and proteinases. TNF-α is a key cytokine, which triggers the 
inflammatory cascade and stimulates the production of matrix degradable proteinases such 
as matrix metalloproteinases (MMPs) (Okada, 2005). TNF-α converting enzyme (TACE) 
processes a membrane form of TNF-α to a soluble form (Moss et al., 1997), and the binding 
of the latter form to TNF receptors triggers pathological events in RA (Christodoulou & 
Choi, 2006; Horiuchi et al., 2010; Ohta et al., 2001). Although synovitis is one of the major 
manifestations of SAPHO syndrome, detailed information on the pathological features is 
still lacking. 
In this chapter, we describe a patient with SAPHO syndrome accompanied by marked knee 
synovitis and acrodermatitis continua of Hallopeau (ACH) as a skin manifestation. ACH is a 
rare acropustular eruption, characterized by sterlile pustules, paronychia and atrophic skin 
changes, onychodystrophy and osteolysis of the distal phalanges of the fingers and toes 
(Ryan et al., 2009). ACH is considered to be a localized subtype of pustular psoriasis 
(Yerushalmi et al., 2000) and our report is a first case of ACH as a skin manifestation of 
SAPHO syndrome. We focused on synovitis, analyzed synovial tissues histopathologically 
and demonstrated the expression of TNF-α, TACE and MMP-3 in SAPHO syndrome 
synovium. We also concisely review cases treated with anti-TNF-αagents in the literature 
and discuss the therapeutic strategy for SAPHO syndrome. 
2. Case report  
A 76-year-old Japanese man first presented to a neighborhood university hospital in 1993 with 
subungal pustules, erythema and onychodystrophy on all fingers and toes. A diagnosis of 
ACH was histologically confirmed at the time. He had been treated with topical corticosteroid 
and vitamin D3. In January 2006, he presented to our department for the first time with 
persistent swelling and pain in his left knee. Physical examination showed marked patellar 
ballottement with local heat. A knee puncture yielded 60mL of yellow cloudy joint fluid, but 
cultures for bacteria were negative. For other osteoarticular symptoms, moderate lower back 
and buttock pain existed but no other joint pain, costa-sterno-clavicular joint included, was 
found. At the time, dermatological symptoms of ACH still remained on all fingers and toes 
(Figure 1a, b). Laboratory tests showed almost within normal value including indices of 
inflammation (erythrocyte sedimentation rate 10mm/hour, C-reactive protein level 
0.19mg/dL [normal <0.30mg/dL]) and rheumatoid factor was negative. Radiographic study 
revealed characteristic osteolysis in phalanges of fingers and toes (Figure 1c, d). Magnetic 
resonance imaging revealed knee synovitis and bone marrow edema at the second lumbar 
vertebral body (Figure 2), compatible with sterile osteitis.  
We made a diagnosis of SAPHO syndrome because the presence of ACH (a variant of 
pustular psoriasis), knee synovitis, and osteitis of the vertebral body were sufficient to the 
criteria. The patient was treated with NSAIDs for osteoarticular symptoms and topical 
treatment for skin lesions. 
In October 2007, arthroscopic surgery was performed for knee synovitis. Intra-operative 
findings showed marked proliferation of villous contoured synovial tissues with rich blood 
circulation (Figure 3a). Continuous paraffin sections of biopsied synovial tissues were used 
for histopathological analyses, and standard microscopic study showed hyperplastic 
synovitis with lymphocytes infiltration and many blood vessels similar to RA (Figure 3b, c, 
d). Immunohistochemistry revealed the expression of TNF-α (Figure 3e), TACE (Figure 3f) 
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Fig. 1. Clinical findings of fingers (a), toes (b), and radiographs of bilateral fingers (c) and 
toes (d) in a patient with SAPHO syndrome accompanied by acrodrmatitis continua of 
Hallopeau. Erythema, pustules and onychodystrophy are present on all fingers and toes, 
which are compatible with the dermatological features of acrodermatitis continua of 
Hallopeau (a, b). Characteristic osteolysis of acrodermatitis continua of Hallopeau are 
observed in phalanges of fingers (c) and toes (d). 
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Fig. 2. Radiographic study (a, b) and magnetic resornance imaging (c, d, e) of lumber spine in a 
patient with SAPHO syndrome accompanied by acrodrmatitis continua of Hallopeau. Bone 
marrow edema at the second lumbar vertebral body (arrow) is compatible with sterile osteitis.  
and MMP-3 (Figure 3g) in synovial cells of the lining layer. TNF-α and TACE were 
expressed dominantly in CD68 positive synovial cells of the lining and sublining layer, 
whereas MMP-3 was expressed dominantly in CD68 negative synovial cells of the lining 
layer (Figure 3e-h). Primary antibodies used for these analyses were polyclonal antibodies 
for TNF-α (654250; Calbiochem, Germany), TACE (sc-25782; Santa Cruz Biotechnology, 
USA), monoclonal antibodies for MMP-3 (55-2A2; Daiichi Fine Chemical Co., Japan) and 
CD68 (M0814; DakoCytomation, Denmark). After arthroscopic synovectomy, his knee 
symptoms immediately diminished. In 2008, additional administration of alendronate (35 
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Fig. 3. Macro- and microscopic findings of knee synovitis in a patient with SAPHO 
syndrome accompanied by acrodrmatitis continua of Hallopeau. Arthroscopy reveals RA 
like villous contoured synovial tissues with rich blood circulation (a). Continuous paraffin 
sections (b-h) were stained with hematoxylin and eosin (b-d) or immunostained with 
antibodies against TNF-α (e), TACE (f), MMP-3 (g), or CD68 (h). Note that hyperplastic 
synovitis with lymphocytes infiltration, rich blood vessels similar to RA (b, c, d), and TNF-α, 
TACE and MMP-3 are expressed in synovial lining cells (e-g).  
www.intechopen.com
 Rheumatoid Arthritis – Treatment 
 
98
mg/week) was started. In the four year follow-up period, there has been no recurrence of 
knee synovitis, no exacerbation of dermatological symptoms of ACH, and the patient has 
had only mild low back pain which have responded to NSAIDs and alendronate. 
3. Discussion 
In the present case, we investigated the histopathological features of SAPHO syndrome 
synovitis. Arthroscopic findings showed moderate proliferation of villous contoured 
synovial tissues with rich blood circulation. Microscopic findings showed hyperplastic 
synovitis with lymphocytes infiltration and many blood vessels. Further 
immunohistochemistry showed that TNF-α and TACE were expressed dominantly in 
CD68 positive macrophage like synovial cells of lining and sublining layer while MMP-3 
was expressed dominantly in CD68 negative fibroblast like synovial cells of lining layer. 
These histopathological features were overlapped with those of RA synovitis. But the extent 
of each microscopic feature, such as hyperplasticity of lining layers, lymphocytes infiltration 
and vascular density, seemed to be more marked in RA than SAPHO syndrome. 
Furthermore, in our previously reported a case of SAPHO syndrome accompanied by 
marked knee synovitis and PPP as a skin manifestation, the histopathological features of 
synovitis were also similar to this case (Komiya et al., 2009). Although it is difficult to 
compare with past cases for lack of reports with detailed histopathological analyses of 
SAPHO syndrome synovitis, it is speculated that TNF-α may be produced abundantly and 
well activated by TACE in SAPHO synovitis, and this condition at least partially have a 
common with RA synovial pathogenesis. 
SAPHO syndrome is characterized by the osteoarticular and dermatological symptoms that 
were compiled by French rheumatologists after a national survey carried in 1987 (Chamot et 
al., 1987). The acronym SAPHO stands for synovitis, acne, pustulosis,  hyperostosis, osteitis 
(Chamot et al., 1987). As described by Kahn et al. in 1994, three diagnostic criteria 
characterize SAPHO syndrome: 1) multifocal osteomyelitis with or without skin 
manifestations; 2) sterlile acute or chronic joint inflammation associated with either pustular 
psoriasis or palmo-plantar pustulosis, or acne, or hidradenitis; 3) sterlile osteitis in the 
presence of one of the skin manifestations (Kahn et al., 1993, 1994). According to Kahn, one 
of the criteria is sufficient for the diagnosis of SAPHO syndrome. 
The etiology and prevalence of SAPHO syndrome has not been determined because of the 
variety in clinical appearance. Although the osteoarticular symptoms of SAPHO syndrome 
are most commonly observed in the anterior chest wall and the spine, the taxonomic concept 
of spinal lesions of SAPHO syndrome is still confused and controversial; whether SAPHO 
synrdome is classified in to seronegative spondyloarthropathy (SNSA) or not (Hayem et al., 
1999; Higashi et al., 2005). Accumulated data suggested that SAPHO syndrome can be 
classified into SNSA; a high prevalence of axial involvement (up to 90%), an increased 
frequency of positive HLA-B27 (15%), and an association with psoriasis and inflammatory 
bowel syndrome in 13% of cases (Ben Abdelghani et al., 2010; Kahn et al., 1992). 
Furthermore, many researchers have supported a link between SAPHO syndrome and 
SNSA. Maugars reported that 43% and 33% of 19 SAPHO syndrome patients fullfilled the 
criteria of European Spondylarthropathy Study Group (ESSG) (Dougados et al., 1991) and 
Amor (Amor et al., 1990), respectively (Maugars et al., 1995). Hukuda et al. reported that 
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4.7% and 0.3% of Japanese 990 SNSA patients showed PPP and SAPHO syndrome, 
respectively (Hukuda et al., 2001). Takigawa et al. reported that 23% of 13 SAPHO 
syndrome patients met the criteria of SNSA regardless of whether ESSG or Amor criteria 
were used (Takigawa et al, 2008). In their series, if PPP is added as a skin lesion to the 
criteria of spondyloarthropathy, 100% and 92% of their cases would fullfill the diagnostic 
criteria of ESSG and Amor, respectively. Sonozaki proposed pustulotic arthro-osteitis is one 
subtype of SNSA (Sonozaki et al., 1981). Thus Takigawa et al. proposed that SAPHO 
syndrome, especially spinal lesions related to PPP, should be recognized as a subtype of 
SNSA (Takigawa et al., 2008). 
The treatment of SAPHO syndrome remains empirical. In practice, NSAIDs are applied 
for osteoarticular symptoms and topical treatment for skin lesions. This first-line 
treatment is effective in two-thirds of cases (Hayem et al., 1999). In cases not respond to 
the first-line treatment, the second-line treatment, including glucocorticoids, BPs, and 
DMARDs such as methotrexate and sulfasalazine, is considered, but results are usually 
inconsistent and insufficient (Hayem et al., 1999). Recently some successful experiences 
with anti-TNF-α agents for recalcitrant cases of SAPHO syndrome have been reported 
(Asmussen, 2003; Ben Abdelghani et al., 2010; Castellvi et al., 2010; Deutschmann et al., 
2005; Iqbal & Kolodney, 2005; Kyriazis et al., 2004; Massara et al., 2006; Moll et al., 2008; 
Olivieri et al., 2002; Sabugo et al., 2008; Wagner et al., 2002; Widmer et al., 2003). This 
therapeutic strategy was largely originated from that for spondyloarthropathies in which 
the efficacy and safety of anti-TNF-α therapy is well established (Davis et al., 2003; Mease 
et al., 2000; Moreland et al., 1999). 
TNF-α is a proinflammatory cytokine found in increased concentrations in the joints and 
skin of patients with RA, pasoriatic arthritis and psoriasis, and plays crucial roles in the 
pathogenesis of these chronic inflammatory disease (Bradley, 2008; Ettehadi et al., 1994; 
Feldmann & Maini, 2001; Partsch et al., 1997; Tutrone et al., 2001). In RA synovium, TNF-α is 
produced abundantly and contribute to the pathogenesis by inducing the production of 
other proinflammatory cytokines, chemokines, and MMPs (Brennan et al., 1995; Ivashkiv, 
1996; MacNaul et al., 1990). TNF-α is generated as a proform called transmembrane TNF-α 
that is consist of 233 amino acid residues (26kDa) and expressed on TNF-α-producing cells 
as a homotrimer (Kriegler et al., 1988; Luettiq et al., 1989; Pennica et al., 1984). This 
transmembrane TNF-α is cleaved between alanine76-valine77 bond by TACE, resulting in 
the release of soluble TNF-α that is consist of 157 amino acid residues (17kDa). Soluble TNF-
α is a homotrimer of 17-kDa cleaved monomers and transmembrane TNF-α also exists as a 
homotrimer of 26-kDa uncleaved monomers (Tang et al., 1996). Both soluble and 
transmembrane TNF-α mediate pleiotrophic effects (apoptosis, cell proliferation and 
cytokine production) through binding to type 1 and type 2 TNF receptors (TNF-R1 and 
TNF-R2), but transmembrane TNF-α is supposed to mediate its biological activities mainly 
through TNF-R2 (Bazzoni & Beutler, 1996; Black et al., 1997; Grell et al., 1995; Moss et al., 
1997; Vandenabeele et al., 1995). The remaining of cytoplasmic domain of transmembrane 
TNF-α after cleavage with TACE migrated back into the nucleus of the transmembrane 
TNF-α-expressing cells and is supposed to mediate cytokine production (Domonkos et al., 
2001). It is very interesting that transmembrane TNF-α transmits signals both as a ligand 
and as a receptor. Differential clinical efficacies of anti-TNF-α agents may be explained by 
their different action on transmembrane TNF-α-expressing cells (Horiuchi et al., 2010). 
www.intechopen.com
 Rheumatoid Arthritis – Treatment 
 
100 
TACE plays a crucial role in post-translational regulation of TNF-α. Binding of soluble TNF-
α to TNF receptors activate various pathological events including the production of MMPs. 
TACE is a member of the ADAM (a disintegrin and metalloproteinase) family proteins, 
which possess characteristics of both cell surface adhesion molecules and proteinases. Some 
of the ADAM family proteins, including TACE, are considered to be responsible for the 
proteolytic processing of ectodomain of various cell surface molecules such as cytokines, 
cytokine receptors, adhesion molecules, and enzymes (Klein & Bischoff, 2011; Okada, 2005; 
Seals & Courtneidge, 2003). Several studies indicate that TACE levels are elevated in RA 
joints compared with osteoarthritis or normal articulations, suggesting that abnormal TACE 
activity contributes to TNF-α action in RA pathogenesis (Ohta et al, 2001). In the present 
case and in our previously reported case (Komiya et al., 2009), we demonstrated the 
expression of TNF-α, TACE and MMP-3 in SAPHO syndrome synovitis, thus it is speculated 
that TACE play roles in the pathogenesis of SAPHO syndrome synovitis through the 
processing of TNF-α, which triggers a cascade of pathological events through a mechanism 
similar to RA. 
To our knowledge, 26 cases of SAPHO syndrome treated with anti-TNF-α agents 
(infliximab, etanercept or adalimumab) have been described, all of them showing a 
sustained response of osteoarticular manifestations (Asmussen, 2003; Ben Abdelghani et al., 
2010; Castellvi et al., 2010; Deutschmann et al., 2005; Iqbal & Kolodney., 2005; Kyriazis et al., 
2004; Massara et al., 2006; Moll et al., 2008; Olivieri et al., 2002; Sabugo et al., 2008; Wagner et 
al, 2002; Widmer et al., 2003), but not favorable for cutaneous manifestations in some cases 
(Ben Abdelghani et al., 2010; Massara et al., 2006). In the 26 previously reported cases in the 
literature, clinical response was rapid after within 2 infusions of anti-TNF-α agent in most of 
cases (24/26 cases, 92%). Clinical response was maintained in all cases, and clinical 
remission, which usually described as no recurrence of osteoarticular pain, was maintained 
with a follow up 8 to 42 months during treatment. Thus it is considered that the efficacy of 
anti-TNF-α agents on osteoarticular symptoms is reliable. Whereas, relapse or worsening of 
the skin lesion after anti-TNF-α therapy was observed in 5/26 cases (19%) (Ben Abdelghani 
et al., 2010; Massara et al., 2006). ACH, a skin lesion of this case, is a rare chronic pustular 
eruption of the distal portions of the hands and feet, characterized by sterlile pustules, 
paronychia and atrophic skin changes, onychodystrophy and osteolysis of the distal 
phalanges (Puig et al., 2010; Ryan et al., 2009). It is considered by many to be a localized 
variant of pustular psoriasis. (Kurooka et al., 2010; Yerushalmi et al., 2000). ACH is 
notoriously difficult to treat, with limited success with numerous agents including topical 
treatments, photochemotherapy, ciclosporin, methotrexate, retinoids, dapson and 
tetracyclines (Nikkels et al., 1999). Recently successful treatment of ACH with anti-TNF-α 
agents have been reported (Ahmad & Rogers, 2007; Bonish et al., 2006; Kazinski et al., 2005; 
Mang et al., 2004; Ryan et al., 2009). But in some cases of ACH, failed treatment with anti-
TNF-α agents have been also reported (Adisen et al., 2007; Thielen et al., 2008; Ryan et al., 
2009). In a recent review, 120 patients (with RA, ankylosing spondylitis, psoriasis, Crohn 
disease, SAPHO syndrome, psoriatic arthritis, and other diagnosis) from the literature who 
developed pustular lesions during treatment with anti-TNF-α agents were reported 
(Wollina et al., 2008). Psoriasis (except palmoplantar pustular type) was the most common 
adverse effect during anti-TNF-α agent treatment (n=73), followed by PPP (n=37). The 
reasons for these negative or paradoxical effects of anti-TNF-α agents on cutaneous 
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manifestations have not yet been determined. One possible reason is that TNF-α is a pivotal 
mediator of the activation of neutrophils (Lebwohl, 2003), because in SAPHO syndrome, 
skin lesions are usually characterized by nuetrophil infiltration similar to those of pustular 
psoriasis. Another possible reason for deterioration of skin pustules could be activation of 
Propionibacterium acnes with anti TNF-α. P. acnes is anaerobic skin saprophyte, which has 
been strongly implicated in SAPHO syndrome (Perry & Lambert, 2006). Assmann et al. 
showed positive bacteriological cultures for P. acnes in 14 of 21 (67%) patients who had 
undergone a needle biopsy of ostitis lesions (Assmann et al., 2009). Rozin reported that P. 
acnes was positive in 38/90 cases (42%) in bone lesions in cases of SAPHO syndrome in the 
literature (Rozin, 2009). Bacterial or viral infections induces rheumatic condition, thus 
P.acnes could be an important pathogen in SAPHO syndrome. Thus, taking into 
consideration of P. acnes, combination of anti-TNF-α agents and antibiotics may prevent the 
exacerbation of skin lesion.  
In cases not respond to the first-line treatment, BPs could be a good therapeutic modality 
except anti-TNF-α agents. Recently some successful treatments of SAPHO syndrome with 
BPs have been reported (Amital et al., 2004; Colina et al., 2009; Siau & Laversuch, 2010). BPs 
are potent inhibitors of osteoclastic bone resorption and are an important therapeutic 
modality in the management of Paget’s disease, multiple myeloma, malignancy-associated 
hypercalcaemia, bone metastasis and osteoporosis. Not only the effect on bone 
remodeling, BPs have also an anti-inflammatory effect by suppressing the production of 
proinflammatory cytokines, such as interleukin (IL)-1, TNF-α, IL-6, and by inhibiting the 
antigen-presenting capacity of macrophages (de Vries et al., 1982; Pennanen et al., 1995). 
Amital et al. reported successful treatment with pamidronate in 10 patients with SAPHO 
syndrome (Amital et al., 2004). Intravenous administration of pamidronate was effective for 
not only osteoarticular manifestations but also skin lesions (Amital et al., 2004). Oral 
administration of BPs is also effective in treating SAPHO syndrome (Ichikawa et al., 2009). 
The modulation ability of BPs for anti-inflammatory cytokines, including TNF-α, could be a 
reason for their efficacy in several rheumatological conditions, such as ankylosing 
spondylitis, hypertrophic osteoarthropathy, reflex sympathetic dystrophy, diabetic 
neuropathic arthropathy and the SAPHO syndrome (de Vries et al., 1982; Garske & Bell, 
2002; Guignard et al., 2002; Kubalek et al., 2001; Maksymowych et al., 2002; Marshall et al., 
2002; Maugars et al., 1995; Pennanen et al., 1995; Selby et al., 1994). Ben Abdelghani et al. 
reported five cases not respond to BPs and four of these cases responded to anti-TNF-α 
therapy (Ben Abdelghani et al., 2010). Thus, anti-TNF-α therapy seems effective even for 
cases resistant to BPs. 
The difficulties in the treatment of SAPHO syndrome are integrated into its complicated, not 
single, pathogenesis. Our experience support the importance of TNF-α and TACE in the 
pathogenesis of SAPHO syndrome, but further investigations are clearly needed to elucidate 
this rare and complicated disorder. 
4. Conclusion 
We describe a rare case of SAPHO syndrome accompanied by marked knee synovitis and 
ACH as a skin manifestation. We demonstrated the expression of TNF-α, TACE and MMP-3 
in SAPHO syndrome synovium and also shown the similarity between SAPHO syndrome 
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and RA synovitis. These new findings support the recently reported successful treatment of 
osteoarticular manifestations of SAPHO syndrome with anti-TNF-α agents. 
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